Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Cell Reports. Medicine|April 12, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancerZhuo Wang, Qing Luo, Jie Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib TreatmentXiaomin Niu, Fatao Liu, Yi Zhou, et al.Scientific Reports|August 18, 2017
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR statusHong Jian, Wei Li, Zhiyong Ma, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2015
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancerShun Lu, Lu Li, Yi Luo, et al.The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.Therapeutic Advances in Medical Oncology|August 2, 2024
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinibYongfeng Yu, Wen Dong, Yanxia Shi, et al.Therapeutic Advances in Medical Oncology|November 7, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring <i>MET</i> exon 14 skipping alterations: a <i>post hoc</i> analysis of a pivotal phase 2 studyYongfeng Yu, Yongxin Ren, Jian Fang, et al.Journal of Hematology & Oncology|May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsZhen Zhou, Zhengping Ding, Jie Yuan, et al.Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.Pageof 9